Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with T2D. Participants and Investigators will be blinded to both study interventions. Humulin® R U-500 (U500/mL), a highly concentrated regular human insulin, will be used as an open-label comparator.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
41 participants in 2 patient groups
Loading...
Central trial contact
Eva Svehlikova, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal